FIRST AMENDMENT TO THE CLINICAL TRIAL AGREEMENTThe Clinical Trial Agreement • October 22nd, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations
This First Amendment to the Clinical Trial Agreement (“First Amendment”) is made on 2019 May 7, 2019 (“Effective Date”) by and between St. Joseph Heritage Healthcare (“Institution”) and Cancer Insight, LLC (“CRO”). CRO and Institution are herein referred to collectively as “Parties.” Individually, each of CRO and Institution is a “Party.”
FIRST AMENDMENT TO THE CLINICAL TRIAL AGREEMENTThe Clinical Trial Agreement • August 30th, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations
This First Amendment to the Clinical Trial Agreement (“First Amendment”) is made on August 28, 2018 (“Effective Date”) by and between Cancer Center of Kansas (“Institution”) and Cancer Insight, LLC (“CRO”). CRO and Institution are herein referred to collectively as “Parties.” Individually, each of CRO and Institution is a “Party.”
AMENDMENT # 1 TO THE CLINICAL TRIAL AGREEMENTThe Clinical Trial Agreement • April 21st, 2021
This Amendment 1 (the “Amendment”) dated 16Feb2021 to the Clinical Trial Agreement, fully executed on 05Feb2019 (the “ Agreement”) for the clinical study conducted in accordance with the Protocol ID-054-304 (REACT) titled: “ A prospective, multi- center, double-blind, randomized, placebo-controlled, parallel-group, Phase 3 study to assess the efficacy and safety of clazosentan in preventing clinical deterioration due to delayed cerebral ischemia (DCI), in adult subjects with aneurysmal subarachnoid hemorrhage (aSAH) ” and any amendments thereto (the “Study”), has been concluded by and between:
FIRST AMENDMENT TO THE CLINICAL TRIAL AGREEMENTThe Clinical Trial Agreement • October 22nd, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations
This First Amendment to the Clinical Trial Agreement (“First Amendment”) is made on August 28, 2018 (“Effective Date”) by and between Cancer Center of Kansas (“Institution”) and Cancer Insight, LLC (“CRO”). CRO and Institution are herein referred to collectively as “Parties.” Individually, each of CRO and Institution is a “Party.”
AMENDMENT 1 TO THE CLINICAL TRIAL AGREEMENTThe Clinical Trial Agreement • January 18th, 2019
This Amendment 1 (the “Amendment”) to the Clinical Trial Agreement, dated 02nd November 2018 (the “ Agreement”) for the clinical study conducted in accordance with the Protocol ID-080A301 / PRECISION titled: “Multi-center, blinded, randomized, PaRallEl- group, Phase 3 study with aproCItentan in Subjects with ResIstant HypertensiON (RHT)" and any amendments thereto (the “Study”), has been concluded by and between:
TO THE CLINICAL TRIAL AGREEMENTThe Clinical Trial Agreement • April 5th, 2022
This 1st Amendment (“1st Amendment”) to the Clinical Trial Agreement is effective as of the date of its publication in Contract Register (the “Effective Date”), is entered by and among the following parties:
AMENDMENT NO. 1 TO THE CLINICAL TRIAL AGREEMENTThe Clinical Trial Agreement • April 8th, 2020
Fakultní nemocnice Hradec Králové (the “Provider”), located at Sokolská 581, 500 05 Hradec Králové – Nový Hraedec Králové, Czech Republic, IČO (Company ID): 00179906, Tax ID: CZ00179906, represented by prof. MUDr. Vladimír Palička, CSc., dr.h.c., director,
TO THE CLINICAL TRIAL AGREEMENTThe Clinical Trial Agreement • April 20th, 2022
This #1 Amendment (“#1 Amendment”) to the Clinical Trial Agreement is effective as of the date date following the day of publication of this Amendment in the Central Register of Contracts (the “Effective Date”), is entered by and among the following parties:
